Status:
RECRUITING
Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
Lead Sponsor:
IRCCS San Raffaele
Collaborating Sponsors:
European Commission
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Conditions:
Glioblastoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This is a prospective multicenter study of hypofractionated radiotherapy for the radiation treatment (RT) of solid tumors and in particular for Glioblastoma (in Aim 2). It is based on the results of o...
Detailed Description
This is a prospective multicenter pilot study. Functional and spectroscopic neuroradiological imaging will be adopted for treatment planning. Specialized software will be used to perform radiomic feat...
Eligibility Criteria
Inclusion
- Diagnosis of Glioblastoma.
- ECOG performance score 0-2 (defined during the first visit)
- Surgically removable lesion (according to the operability criteria established by the Neurosurgery Unit)
- For healthy volunteers, people who are as comparable as possible with the patient population in terms of sex and age will be recruited
Exclusion
- Previous stroke
- Presence of another primary and/or metastatic tumor For healthy volunteers also, absence of primary and/or metastatic tumor
Key Trial Info
Start Date :
August 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06551909
Start Date
August 31 2024
End Date
February 28 2027
Last Update
June 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS San Raffaele Scientific Institute
Milan, MI, Italy, 20132